RUNX1 mutations influence the efficacy of anthracyclines and cytarabine in treating acute myeloid leukemia (AML) by affecting the gene's role in transcription and cellular differentiation in hematologic pathways. Patients with specific RUNX1 profiles may have altered sensitivity or resistance to these drugs, necessitating dosage adjustments to optimize treatment outcomes.